| 2024 |
| 04/17 | 313 | 321 | 307 | 315 | +1.61% | 299,100 | 37億2645万 | -5.41% |
| 04/16 | 313 | 317 | 307 | 310 | -2.21% | 170,600 | 36億6730万 | -7.46% |
| 04/15 | 318 | 321 | 314 | 317 | -0.94% | 177,900 | 37億5011万 | -5.93% |
| 04/12 | 318 | 323 | 314 | 320 | +0.63% | 185,900 | 37億8560万 | -5.88% |
| 04/11 | 313 | 319 | 310 | 318 | +0.95% | 146,200 | 37億6194万 | -7.29% |
| 04/10 | 316 | 323 | 311 | 315 | -1.25% | 188,700 | 37億2645万 | -9.22% |
| 04/09 | 307 | 322 | 307 | 319 | +2.24% | 275,600 | 37億7377万 | -8.86% |
| 04/08 | 312 | 313 | 305 | 312 | -0.32% | 184,400 | 36億9096万 | -11.61% |
| 04/05 | 313 | 319 | 303 | 313 | -2.49% | 386,100 | 37億279万 | -12.57% |
| 04/04 | 303 | 331 | 301 | 321 | +6.29% | 559,400 | 37億9743万 | -11.57% |
| 04/03 | 301 | 310 | 300 | 302 | -1.95% | 310,800 | 35億7266万 | -17.71% |
| 04/02 | 318 | 320 | 307 | 308 | -4.64% | 443,800 | 36億4364万 | -17.65% |
| 04/01 | 15:05 第三者割当による第28回新株予約権(行使価額修正条項付)の月間行使状況に関するお知らせ |
| 04/01 | 332 | 333 | 321 | 323 | -3.29% | 257,300 | 38億2109万 | -15% |
| 03/29 | 326 | 340 | 325 | 334 | +2.77% | 274,400 | 39億5122万 | -12.57% |
| 03/28 | 332 | 337 | 325 | 325 | -2.99% | 269,000 | 38億4475万 | -15.58% |
| 03/27 | 332 | 342 | 332 | 335 | 0% | 221,300 | 39億6305万 | -14.76% |
| 03/26 | 350 | 350 | 335 | 335 | -4.56% | 424,700 | 39億6305万 | -16.46% |
| 03/25 | 364 | 366 | 350 | 351 | -3.31% | 402,400 | 41億5233万 | -14.18% |
| 03/22 | 15:05 国立研究開発法人日本医療研究開発機構(AMED)令和6年度「革新的がん医療実用化研究事業」への採択のお知らせ |
| 03/22 | 369 | 369 | 356 | 363 | -2.16% | 344,400 | 42億9429万 | -12.95% |
| 03/21 | 364 | 375 | 360 | 371 | +2.49% | 340,800 | 43億8893万 | -11.88% |
| 03/19 | 355 | 371 | 354 | 362 | +1.12% | 383,700 | 42億8246万 | -15.02% |
| 03/18 | 347 | 367 | 347 | 358 | +0.85% | 423,100 | 42億3514万 | -17.13% |
| 03/15 | 369 | 369 | 354 | 355 | -5.08% | 378,100 | 41億9965万 | -18.95% |
| 03/14 | 366 | 374 | 361 | 374 | +2.75% | 243,600 | 44億2442万 | -15.77% |
| 03/13 | 376 | 376 | 360 | 364 | -2.15% | 311,400 | 43億612万 | -19.11% |
| 03/12 | 370 | 378 | 362 | 372 | +1.09% | 352,000 | 44億76万 | -18.6% |
| 03/11 | 380 | 384 | 361 | 368 | -4.17% | 646,200 | 43億5344万 | -21.03% |
| 03/08 | 17:15 主要株主の異動に関するお知らせ |
| 03/08 | 391 | 398 | 381 | 384 | -2.29% | 369,900 | 45億4272万 | -19.5% |
| 03/07 | 15:05 第三者割当による第28回新株予約権(行使価額修正条項付)の発行に係る払込完了に関するお知らせ |
| 03/07 | 404 | 411 | 391 | 393 | -3.2% | 333,600 | 46億4919万 | -19.14% |
| 03/06 | 403 | 414 | 397 | 406 | +2.53% | 470,000 | 48億298万 | -17.81% |
| 03/05 | 19:45 TOKYO戦略的イノベーション促進事業への採択のお知らせ |
| 03/05 | 400 | 404 | 388 | 396 | -1.98% | 580,000 | 46億8468万 | -21.43% |
| 03/04 | 416 | 417 | 398 | 404 | -5.16% | 768,000 | 47億7932万 | -21.25% |
| 03/01 | 428 | 494 | 416 | 426 | -2.29% | 3,116,900 | 50億3958万 | -18.39% |
| 02/29 | 444 | 448 | 417 | 436 | -0.46% | 1,117,600 | 51億5788万 | -17.74% |
| 02/28 | 467 | 467 | 431 | 438 | -6.01% | 1,463,000 | 51億8154万 | -18.28% |
| 02/27 | 500 | 531 | 453 | 466 | +3.33% | 9,342,800 | 55億1278万 | -14.5% |
| 02/26 | 365 | 451 | 365 | 451 | +21.56% | 3,049,900 | 53億3533万 | -18.15% |
| 02/22 | 386 | 403 | 362 | 371 | -11.24% | 2,912,500 | 43億8893万 | -33.51% |
| 02/21 | 418 | 418 | 418 | 418 | -19.31% | 34,100 | 49億4494万 | -26.41% |
| 02/20 | 16:05 資金調達に関するご説明 |
| 02/20 | 16:05 第三者割当による第28回新株予約権(行使価額修正条項付)の発行及び第三者割当契約の締結に関するお知らせ |
| 02/20 | 540 | 540 | 507 | 518 | -3.36% | 636,600 | 61億2794万 | -10.23% |
| 02/19 | 521 | 541 | 513 | 536 | -0.37% | 772,200 | 63億4088万 | -7.9% |
| 02/16 | 565 | 580 | 538 | 538 | -3.06% | 1,299,400 | 63億6454万 | -8.5% |
| 02/15 | 524 | 555 | 507 | 555 | +16.84% | 633,700 | 65億6565万 | -6.41% |
| 02/14 | 15:05 営業外収益及び特別損失の計上に関するお知らせ |
| 02/14 | 15:05 2024年3月期第3四半期決算短信〔日本基準〕(非連結) |
| 02/14 | 486 | 490 | 470 | 475 | -3.26% | 507,800 | 56億1925万 | -20.57% |
| 02/13 | 485 | 500 | 478 | 491 | -1.21% | 509,900 | 58億853万 | -19.11% |
| 02/09 | 497 | 511 | 494 | 497 | -1.97% | 330,500 | 58億7951万 | -19.45% |
| 02/08 | 504 | 516 | 498 | 507 | -1.55% | 521,500 | 59億9781万 | -18.88% |
| 02/07 | 521 | 530 | 498 | 515 | -1.72% | 923,200 | 60億9245万 | -18.25% |
| 02/06 | 544 | 549 | 516 | 524 | -3.68% | 996,200 | 61億9892万 | -17.22% |
| 02/05 | 561 | 588 | 541 | 544 | -9.33% | 1,486,100 | 64億3552万 | -14.06% |
| 02/02 | 15:39 (訂正)「PPMX-T003:真性多血症(PV)第I相試験終了時期変更のお知らせ」の一部訂正について |
| 02/02 | 15:05 PPMX-T003:真性多血症(PV)第I相試験終了時期変更のお知らせ |
| 02/02 | 625 | 630 | 600 | 600 | -4.91% | 488,000 | 70億9800万 | -5.06% |
| 02/01 | 600 | 643 | 592 | 631 | +3.78% | 682,400 | 74億6473万 | +0.16% |
| 01/31 | 605 | 615 | 596 | 608 | +0.5% | 356,000 | 71億9264万 | -2.88% |
| 01/30 | 638 | 648 | 605 | 605 | -5.17% | 585,100 | 71億5715万 | -3.2% |
| 01/29 | 644 | 656 | 632 | 638 | -0.31% | 360,200 | 75億4754万 | +2.08% |
| 01/26 | 633 | 651 | 619 | 640 | +1.11% | 534,900 | 75億7120万 | +2.73% |
| 01/25 | 620 | 635 | 599 | 633 | +2.59% | 680,300 | 74億8839万 | +1.61% |
| 01/24 | 601 | 630 | 599 | 617 | +3.87% | 624,900 | 72億9911万 | -1.12% |
| 01/23 | 648 | 648 | 590 | 594 | -8.33% | 1,255,500 | 70億2702万 | -4.65% |
| 01/22 | 630 | 655 | 626 | 648 | +3.18% | 406,200 | 76億3992万 | +4.01% |
| 01/19 | 630 | 642 | 615 | 628 | -0.16% | 420,300 | 74億412万 | +1.13% |
| 01/18 | 610 | 629 | 603 | 629 | +1.94% | 525,700 | 74億1591万 | +1.45% |
| 01/17 | 637 | 645 | 610 | 617 | -1.91% | 916,100 | 72億7443万 | -0.96% |
| 01/16 | 657 | 671 | 629 | 629 | -4.41% | 1,002,200 | 74億1591万 | 0% |
| 01/15 | 689 | 703 | 658 | 658 | -4.08% | 1,016,900 | 77億5782万 | +3.79% |
| 01/12 | 666 | 691 | 646 | 686 | +3% | 974,300 | 80億8794万 | +7.69% |
| 01/11 | 686 | 693 | 635 | 666 | -1.48% | 1,539,700 | 78億5214万 | +4.39% |
| 01/10 | 679 | 704 | 656 | 676 | -3.43% | 1,806,800 | 79億7004万 | +5.46% |
| 01/09 | 730 | 765 | 689 | 700 | -3.85% | 2,054,600 | 82億5300万 | +8.86% |
| 01/05 | 710 | 744 | 683 | 728 | +2.97% | 2,896,100 | 85億8312万 | +13.04% |
| 01/04 | 620 | 718 | 620 | 707 | +14.4% | 3,490,500 | 83億3553万 | +9.95% |
| 2023 |
| 12/29 | 599 | 626 | 575 | 618 | +4.92% | 2,622,300 | 72億8622万 | -4.33% |
| 12/28 | 19:45 主要株主である筆頭株主の異動に関するお知らせ |
| 12/28 | 533 | 605 | 529 | 589 | +11.55% | 2,792,300 | 69億4431万 | -9.52% |
| 12/27 | 600 | 615 | 527 | 528 | -0.56% | 4,704,600 | 62億2512万 | -20% |
| 12/26 | 18:00 PPMX-T003:日本における特許登録のお知らせ |
| 12/26 | 527 | 548 | 524 | 531 | -1.12% | 728,200 | 62億6049万 | -20.51% |
| 12/25 | 545 | 553 | 518 | 537 | -0.19% | 954,000 | 63億3123万 | -20.68% |
| 12/22 | 582 | 601 | 530 | 538 | -7.56% | 1,911,800 | 63億4302万 | -21.11% |
| 12/21 | 590 | 605 | 581 | 582 | -2.35% | 477,500 | 68億4397万 | -14.66% |
| 12/20 | 590 | 613 | 579 | 596 | -0.5% | 762,100 | 70億860万 | -12.09% |
| 12/19 | 631 | 634 | 590 | 599 | -6.84% | 1,366,600 | 70億4388万 | -10.86% |
| 12/18 | 634 | 679 | 634 | 643 | -0.16% | 1,202,200 | 75億6129万 | -3.31% |
| 12/15 | 596 | 653 | 570 | 644 | +5.92% | 1,759,500 | 75億7305万 | -1.83% |
| 12/14 | 614 | 623 | 584 | 608 | +1% | 739,200 | 71億4971万 | -6.32% |
| 12/13 | 595 | 632 | 587 | 602 | +2.56% | 1,121,200 | 70億7915万 | -6.23% |
| 12/12 | 595 | 612 | 559 | 587 | -3.77% | 1,687,500 | 69億276万 | -7.85% |
| 12/11 | 686 | 695 | 589 | 610 | -10.82% | 2,963,500 | 71億7323万 | -3.33% |
| 12/08 | 755 | 760 | 669 | 684 | -11.86% | 1,774,400 | 80億4342万 | +9.79% |
| 12/07 | 774 | 794 | 741 | 776 | +1.44% | 880,800 | 91億2529万 | +26.59% |
| 12/06 | 734 | 777 | 730 | 765 | +4.79% | 865,000 | 89億9594万 | +27.71% |
| 12/05 | 701 | 736 | 685 | 730 | +2.38% | 1,038,700 | 85億8436万 | +24.57% |
| 12/04 | 746 | 783 | 711 | 713 | -4.3% | 1,383,200 | 83億8445万 | +24.22% |
| 12/01 | 16:00 第２回日本抗体学会学術大会における講演を行いました |
| 12/01 | 713 | 751 | 691 | 745 | +2.48% | 1,561,600 | 87億6075万 | +32.09% |
| 11/30 | 694 | 741 | 689 | 727 | +3.27% | 1,579,600 | 85億4908万 | +31.23% |
| 11/29 | 695 | 725 | 662 | 704 | -0.56% | 2,189,400 | 82億7861万 | +28.94% |
| 11/28 | 793 | 795 | 695 | 708 | -9% | 3,014,600 | 83億2565万 | +32.34% |
| 11/27 | 732 | 797 | 712 | 778 | +5.28% | 3,557,500 | 91億4881万 | +48.47% |
| 11/24 | 807 | 874 | 716 | 739 | -11.71% | 7,169,000 | 86億9019万 | +44.34% |
| 11/22 | 727 | 879 | 721 | 837 | +14.81% | 7,921,600 | 98億4261万 | +67.07% |
| 11/21 | 758 | 780 | 687 | 729 | -2.67% | 8,027,600 | 85億7260万 | +50% |
| 11/20 | 640 | 749 | 632 | 749 | +15.41% | 9,525,600 | 88億779万 | +57.35% |
| 11/15 | 16:00 2024年3月期第2四半期決算説明会資料 |
| 11/13 | 15:05 営業外収益及び特別損失の計上に関するお知らせ |
| 11/13 | 15:05 2024年3月期第2四半期決算短信〔日本基準〕(非連結) |
